Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review.
about
Vedolizumab for induction and maintenance of remission in Crohn’s diseaseAdvances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2Therapeutic drug monitoring in inflammatory bowel diseaseOptimizing the use of biological therapy in patients with inflammatory bowel diseaseUstekinumab in treatment of Crohn's disease: design, development, and potential place in therapyNext-Generation Therapeutics for IBDCurrent, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.Assessment of corticosteroid-related quality of care measures for ulcerative colitis and Crohn's disease in the United States: a claims data analysis.Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United StatesDoes long-term efficacy differ between infliximab and adalimumab after 1 year of continuous administration?: A STROBE-compliant retrospective cohort study.Systematic review with meta-analysis: the efficacy and safety of stem cell therapy for Crohn's diseaseUpdate on the management of inflammatory bowel disease: specific role of adalimumab.From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's diseaseOptimizing the use of anti-tumor necrosis factor in the management of patients with Crohn's disease.The Value of Vedolizumab as Rescue Therapy in Moderate-Severe Crohn's Disease Patients with Adalimumab Non-response in the USA.Combination therapy for the treatment of Crohn's disease.Effectiveness and Safety of Immunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's DiseaseMatricellular Protein Periostin Mediates Intestinal Inflammation through the Activation of Nuclear Factor κB Signaling.Efficacy of Adalimumab in Korean Patients with Crohn's Disease.Efficacy and Safety of Escalation of Adalimumab Therapy to Weekly Dosing in Pediatric Patients with Crohn's Disease.Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximabClinical effects of adalimumab treatment with concomitant azathioprine in Japanese Crohn's disease patients.Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitisNon-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study.Fermented Pueraria Lobata extract ameliorates dextran sulfate sodium-induced colitis by reducing pro-inflammatory cytokines and recovering intestinal barrier function.Management of Crohn's disease in poor responders to adalimumab.Review article: remission rates achievable by current therapies for inflammatory bowel disease.Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use?Surgery for Crohn's disease in the era of biologicals: a reduced need or delayed verdict?Mechanism and therapeutic strategy of secondary failure to anti-tumor necrosis factor-α monoclonal antibody treatment for Crohn's disease.Personalizing therapy for inflammatory bowel diseases.Targeting TNF-α for the treatment of inflammatory bowel disease.Tailoring anti-TNF therapy in IBD: drug levels and disease activity.Translational research and efficacy of biologics in Crohn's disease: a cautionary tale.Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives.TNF blocking therapies and immunomonitoring in patients with inflammatory bowel diseasePharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis.Inflammatory bowel disease meta-evidence and its challenges: is it time to restructure surgical research?Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it?Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
P2860
Q24187571-92589213-697B-4B9B-912E-95EECA512B9EQ26798299-00D47543-69C4-49AF-AEAD-30A0450FE56AQ26852729-3126A961-8023-4C53-A7C0-F397D3DD671EQ27025513-9BE76966-E166-41D5-8639-F78AA966FB6AQ28067631-BBF2D36D-5E61-4175-8314-0862D11638CFQ28082306-680FB16E-27B6-40D0-9D34-76FCE79F16E3Q30902172-56733464-A730-4A0C-95FC-BDA7E3C770CEQ31146183-408B51FC-BF2D-4D98-9754-6CE46283EE97Q33584629-FA57DC5F-6C0A-4EFC-9493-8EEF8DFFFD46Q33606172-49C0E945-938A-4703-A2DB-CC485933DA6EQ33768359-FF849A59-71F7-4857-A9D8-73A35CB68921Q35186975-A614C5E7-0AB3-438B-8606-58EC42BC47C0Q35559305-886DE705-EDDF-43E0-AC26-9F50F381F832Q35561386-00D8FDEF-8959-48E9-B9DD-A1BC978FEF82Q35634736-6673BE76-3D77-49A3-9F13-D2930701E30BQ35714202-CD094F7E-F2A9-43DF-8D9C-2600435AF38BQ35763489-A6831459-3E9A-436E-893A-6E41A749D8EAQ35927164-8B3C11A4-2BAE-489E-AC1C-E59612A1020CQ36658432-A1FCDCBF-C2BC-4DE7-96C2-25B268DCAC40Q36692562-BAE997D6-C1B8-4CBD-80E0-90CF265B8299Q36714704-7699E158-B283-4FF6-AF05-87D1BE75FA6AQ36819607-E059EE92-BDFA-4392-BC90-4B5ED36301CCQ36882311-6E46127E-8A9B-4D66-8BBC-B0115ECA8689Q37118400-AE9E23CA-EAFD-4B78-9054-CE278CBBCC47Q37325113-3791C8CF-4A59-4AEF-9895-8A7D4D5BEF15Q37708656-3757F220-6D0F-476E-BE7B-5F522E15B9A0Q37842605-AB7562EA-3FDA-4B78-B023-BD8E1A0C0EE9Q37965581-88EA1E23-6155-4DC1-96F8-9AA9025DF7D7Q38033153-C361D74D-B18C-49BE-99BA-56657CAD9C9DQ38116746-CBED0170-117D-4555-B905-8ED88B61F64FQ38132279-492D0D40-36FB-47C2-8948-3D3A5A066096Q38160905-2678D1E6-C2B6-43DC-8CC2-4FFE2F8669D3Q38176154-34EBB938-2560-4D71-A689-E260887E63C7Q38177338-4EDF4C5C-0C53-4703-8413-9EA75988B045Q38193349-1C2F42CC-09F8-40F8-BB0E-0AB403EDC52AQ38206507-062A2116-6F85-4393-92A4-6F195D865DFAQ38211991-30EE8F06-DC3A-4C9D-9084-31A4BBFF47E4Q38302725-96B279A0-2337-41A8-A99A-F6993E0E16ECQ38337716-A8BE1B94-6F8F-4477-ACA4-70D6DFAD6453Q38344622-D650675D-92FF-463E-8D2C-4B3995BE0B20
P2860
Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Loss of response and need for ...... disease: a systematic review.
@en
Loss of response and need for ...... disease: a systematic review.
@nl
type
label
Loss of response and need for ...... disease: a systematic review.
@en
Loss of response and need for ...... disease: a systematic review.
@nl
prefLabel
Loss of response and need for ...... disease: a systematic review.
@en
Loss of response and need for ...... disease: a systematic review.
@nl
P2860
P356
P1476
Loss of response and need for ...... disease: a systematic review.
@en
P2093
Vincent Billioud
P2860
P304
P356
10.1038/AJG.2011.60
P407
P577
2011-03-15T00:00:00Z